Community Pharmacist Engagement in HIV and HCV Prevention: Current Practices and Potential for Service Uptake

Overview

Journal Explor Res Clin Soc Pharm

Date 2022 Apr 28

PMID 35479840

Authors

KariLynn Dowling-McClay

Stephanie M Mathis

Nicholas Hagemeier

Affiliations

Soon will be listed here.

Abstract

Background: The central Appalachian region is at an elevated risk for HIV/HCV outbreaks, primarily due to injection drug use. Regional risk assessments highlight gaps in the evidence-based continuum of primary, secondary, and tertiary prevention strategies to minimize HIV/HCV transmission. One potential strategy for increasing the reach of HIV/HCV prevention efforts in rural areas is through provision of services at community pharmacies.

Objective: To qualitatively describe community pharmacists' HIV/HCV-related prevention behaviors, attitudes, and beliefs in a 3-state central Appalachian region.

Methods: Key informant interviews were conducted with 15 practicing community pharmacists. Theory of Planned Behavior-based questions probed for perceptions about the role of pharmacies in preventing and reducing HIV/HCV outbreaks in rural areas through activities such as syringe services, screening for HIV/HCV, and linking people to treatment when appropriate. Investigators applied thematic analysis to deductively and inductively generate themes from the interview transcripts.

Results: Two overarching themes regarding pharmacist engagement in HIV/HCV-related prevention services were generated: 1) current approaches to primary prevention through nonprescription syringe sales (e.g., gatekeeping behaviors) and 2) potential for uptake of the continuum of HIV/HCV-related prevention services in community pharmacies. Future engagement of community pharmacists in the continuum of HIV/HCV-related prevention services comprised 2 subthemes as possible underlying factors: general and specific willingness to provide services and perceived fit within the pharmacy profession.

Conclusions: Central Appalachian community pharmacists express a general willingness to help patients who may benefit from HIV/HCV-related prevention services, but current engagement, willingness, and perceived fit for offering specific prevention services in the community pharmacy setting is variable. This has potential immediate implications, such as prioritizing the introduction of more widely accepted services (e.g., provision of HIV/HCV-related prevention education) to community pharmacy practice, and longer-term implications, such as the integration and framing of HIV/HCV-related prevention services as helping behavior within the pharmacist professional identity.

Citing Articles

A qualitative inquiry into the patient-related barriers to linkage and retention in HIV care within the community setting.

Tarfa A, Pecanac K, Shiyanbola O Explor Res Clin Soc Pharm. 2022; 9:100207.

PMID: 36568895 PMC: 9772845. DOI: 10.1016/j.rcsop.2022.100207.

References

Bixler D, Corby-Lee G, Proescholdbell S, Ramirez T, Kilkenny M, LaRocco M . Access to Syringe Services Programs - Kentucky, North Carolina, and West Virginia, 2013-2017. MMWR Morb Mortal Wkly Rep. 2018; 67(18):529-532. PMC: 5944974. DOI: 10.15585/mmwr.mm6718a5. View

McCree D, Byrd K, Johnston M, Gaines M, Weidle P . Roles for Pharmacists in the "Ending the HIV Epidemic: A Plan for America" Initiative. Public Health Rep. 2020; 135(5):547-554. PMC: 7485061. DOI: 10.1177/0033354920941184. View

Lewis C, Rivera A, Crawford N, DeCuir J, Amesty S . Pharmacy-randomized intervention delivering HIV prevention services during the syringe sale to people who inject drugs in New York City. Drug Alcohol Depend. 2015; 153:72-7. PMC: 6688752. DOI: 10.1016/j.drugalcdep.2015.06.006. View

Crawford N, Myers S, Young H, Klepser D, Tung E . The Role of Pharmacies in the HIV Prevention and Care Continuums: A Systematic Review. AIDS Behav. 2021; 25(6):1819-1828. PMC: 8084889. DOI: 10.1007/s10461-020-03111-w. View

Hill L, Ballard C, Cachay E . The Role of the Clinical Pharmacist in the Management of People Living with HIV in the Modern Antiretroviral Era. AIDS Rev. 2019; 21(4):195-210. DOI: 10.24875/AIDSRev.19000089. View

Meyerson B, Davis A, Agley J, Shannon D, Lawrence C, Ryder P . Predicting pharmacy syringe sales to people who inject drugs: Policy, practice and perceptions. Int J Drug Policy. 2018; 56:46-53. PMC: 6375077. DOI: 10.1016/j.drugpo.2018.02.024. View

Fraser H, Zibbell J, Hoerger T, Hariri S, Vellozzi C, Martin N . Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic. Addiction. 2017; 113(1):173-182. PMC: 6211174. DOI: 10.1111/add.13948. View

Fernandes R, Cary M, Duarte G, Jesus G, Alarcao J, Torre C . Effectiveness of needle and syringe Programmes in people who inject drugs - An overview of systematic reviews. BMC Public Health. 2017; 17(1):309. PMC: 5387338. DOI: 10.1186/s12889-017-4210-2. View

Min A, Andres J, Grover A, Megherea O . Pharmacist Comfort and Awareness of HIV and HCV Point-of-Care Testing in Community Settings. Health Promot Pract. 2019; 21(5):831-837. DOI: 10.1177/1524839919857969. View

10.

Rose V, Lutnick A, Kral A . Feasibility of providing interventions for injection drug users in pharmacy settings: a case study among San Francisco pharmacists. J Psychoactive Drugs. 2014; 46(3):226-32. PMC: 4112371. DOI: 10.1080/02791072.2014.921745. View

11.

Stopka T, Donahue A, Hutcheson M, Green T . Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015. J Am Pharm Assoc (2003). 2017; 57(2S):S34-S44. PMC: 5352522. DOI: 10.1016/j.japh.2016.12.077. View

12.

Elliott T, Sanders E, Doherty M, Ndungu T, Cohen M, Patel P . Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review. J Int AIDS Soc. 2019; 22(12):e25419. PMC: 6918508. DOI: 10.1002/jia2.25419. View

13.

Mattingly 2nd T, Pandit N, Onukwugha E . Burden of Co-Infection: A Cost Analysis of Human Immunodeficiency Virus in a Commercially Insured Hepatitis C Virus Population. Infect Dis Ther. 2019; 8(2):219-228. PMC: 6522558. DOI: 10.1007/s40121-019-0240-7. View

14.

Aspinall E, Nambiar D, Goldberg D, Hickman M, Weir A, Van Velzen E . Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol. 2013; 43(1):235-48. DOI: 10.1093/ije/dyt243. View

15.

Sawangjit R, Khan T, Chaiyakunapruk N . Effectiveness of pharmacy-based needle/syringe exchange programme for people who inject drugs: a systematic review and meta-analysis. Addiction. 2016; 112(2):236-247. DOI: 10.1111/add.13593. View

16.

Briggs A . Pharmacists' increasing involvement in hepatitis C management and prevention. J Am Pharm Assoc (2003). 2018; 58(1):5-6. DOI: 10.1016/j.japh.2017.12.008. View

17.

Abdul-Quader A, Feelemyer J, Modi S, Stein E, Briceno A, Semaan S . Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review. AIDS Behav. 2013; 17(9):2878-92. PMC: 6509353. DOI: 10.1007/s10461-013-0593-y. View

18.

Dong B, Lopez M, Cocohoba J . Pharmacists performing hepatitis C antibody point-of-care screening in a community pharmacy: A pilot project. J Am Pharm Assoc (2003). 2017; 57(4):510-515.e2. DOI: 10.1016/j.japh.2017.04.463. View

19.

Durham D, Skrip L, Bruce R, Vilarinho S, Elbasha E, Galvani A . The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States. Clin Infect Dis. 2015; 62(3):298-304. PMC: 4706637. DOI: 10.1093/cid/civ894. View

20.

Schranz A, Barrett J, Hurt C, Malvestutto C, Miller W . Challenges Facing a Rural Opioid Epidemic: Treatment and Prevention of HIV and Hepatitis C. Curr HIV/AIDS Rep. 2018; 15(3):245-254. PMC: 6085134. DOI: 10.1007/s11904-018-0393-0. View